To determine the efficacy of combining minimally invasive keyhole craniotomy (MIKC) and Cs-131 brachytherapy for local control, toxicity, and radiation necrosis in patients with newly diagnosed brain oligometastases, specifically focusing on the impact on survival and quality of life.
Key Findings:
Cs-131 SBT demonstrated lower rates of radiation necrosis compared to I-125, with statistical significance.
MIKC resulted in reduced trauma and faster recovery compared to conventional techniques, supported by recovery time metrics.
Combination of MIKC and Cs-131 SBT showed potential for effective local tumor control and improved functional outcomes, with specific data on survival rates.
Interpretation:
The study suggests that the combination of MIKC and Cs-131 brachytherapy may enhance treatment outcomes for patients with newly diagnosed brain oligometastases, particularly in terms of local control and reduced complications.
Limitations:
Small sample size of 21 patients limits generalizability and may introduce bias.
Focus on newly diagnosed tumors may not reflect outcomes in recurrent cases.
Short follow-up period may not capture long-term effects, necessitating further research.
Conclusion:
Combining minimally invasive keyhole craniotomy with Cs-131 brachytherapy appears promising for treating brain oligometastases, warranting further investigation in larger cohorts to validate these findings.
